Abstract:Abstract Liver cancer is the 5th most common cancer type and the 3rd leading cause of cancer related death worldwide. In the US, the number of new cases continues to rise and reached 19,000 per year in 2004, more than doubling the number twenty years ago. The limited treatment options include surgery, radiation therapy and chemotherapy. Unfortunately, the prognosis for most liver cancer patients is extremely poor due to late diagnosis, and the 5 year overall survival rate is less than 10%. Recent approval of sorafenib suggests that VEGFR inhibition might be beneficial to the survival of HCC patients. Hepatocellular carcinoma (HCC) originates from hepatocytes and accounts for 80–90% of the cases of liver cancer. Genetic alterations found in human HCCs include loss of major tumor suppressor genes (p53, Ink4a/Arf, PTEN, and NF1) as well as activation of oncogenic pathways through mutation and/or amplification (RAS/MapK, PI3K, and Wnt/beta-catenin pathways). We generated primary HCCs in mouse using a recently-developed tissue reconstitution approach. Briefly, we isolated hepatoblasts from p53 deficient donor embryos, infected the cells with retroviruses carrying the clinically relevant human oncogenes Myc or mutant Kras, and transplanted them back to the liver of recipient mice through intra-splenic injection. These mice developed tumors in the liver with a latency of 2–5 months and penetrance of 30–50%. Histological examination demonstrated that these tumors resemble the features of human HCCs. Interestingly, a quantitative analysis of the vasculature in these tumors revealed a broad range of vessel size and vessel density, indicating that angiogenesis in these tumors are likely driven by different molecular mechanisms. We sought to explore the variation in angiogenic phenotypes by examining the response of various tumors with the ATP competitive small molecule VEGFR inhibitor tivozanib (AV-951). Tivozanib exhibits picomolar inhibitory activity against all three VEGF receptors, a multi-day T1/2 in humans, and demonstrates robust clinical activity demonstrated in renal cell carcinoma, the signal tumor type for VEGF pathway inhibition. Consistent with the variation in angiogenic phenotypes, variation in response to tivozanib was observed: a subset of these tumors exhibited exquisite sensitivity to tivozanib, whereas other tumors were significantly less sensitive. These results are in line with the clinical benefit of Sorafenib on patients with hepatocellular carcinoma. These data, taken together, strongly suggest that anti-angiogenesis therapy can be a potential treatment option for a subset of HCC patients. Since our HCC models captured the response of human HCCs, they provide a valuable tool for identification of biomarkers for patient selection. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A12.

In Vitro Regulation of Hepatocellular Carcinoma Cell Viability, Apoptosis, Invasion, and AEG-1 Expression by LY294002

In vitro and in vivo study of BZG-4000: Anti-tumoral activity of human hepatocellular carcinoma

Inhibitory Effect of EGFR Antisense Oligodeoxynucleotide on Human Hepatoma Cell Line.

Hypoxia-inducible Factor-1 Signaling Pathway Influences the Sensitivity of HCC827 Cells to Gefitinib.

CBL0137 Administration Suppresses Human Hepatocellular Carcinoma Cells Proliferation and Induces Apoptosis Associated with Multiple Cell Death Related Proteins.

Effect of inhibitory action of LY294002 in the PI3K/AKT signaling pathway on gastric adenocarcinoma SGC-7901 cells

The Aryl Hydrocarbon Receptor Ligand ITE Inhibits Cell Proliferation and Migration and Enhances Sensitivity to Drug-Resistance in Hepatocellular Carcinoma.

Effects of inhibiting PI3K/AKT/mTOR signaling pathway by LY294002 on gastric cancer MGC-803 cells

Glycyrrhizic Acid Modulates Apoptosis through Extrinsic/Intrinsic Pathways and Inhibits Protein Kinase B- and Extracellular Signal-Regulated Kinase-Mediated Metastatic Potential in Hepatocellular Carcinoma <i>In Vitro</i> and <i>In Vivo</i>

Novel 2-Phenyloxypyrimidine Derivative Induces Apoptosis and Autophagy Via Inhibiting PI3K Pathway and Activating MAPK/ERK Signaling in Hepatocellular Carcinoma Cells.

Abstract C68: Suppression of AKT/mTOR Antiapoptotic Signaling by a Novel Drug Candidate Results in Growth Arrest and Apoptosis of Hepatocellular Carcinoma-Derived Cell Lines.

LY294002 Suppresses Autophagy,Proliferation,Migration and Invasion of Lung Cancer Cells in Vitro

EH-42, a Novel Small Molecule Induces Apoptosis and Inhibits Migration and Invasion of Human Hepatoma Cells Through Suppressing STAT3 Signaling Pathway.

Glycyrrhizic Acid Modulates Apoptosis through Extrinsic/Intrinsic Pathways and Inhibits Protein Kinase B- and Extracellular Signal-Regulated Kinase-Mediated Metastatic Potential in Hepatocellular Carcinoma In Vitro and In Vivo .

Effects of Ly294002 on the Invasiveness of Human Gastric Cancer in Vivo in Nude Mice

MiR-875-5p Inhibits Hepatocellular Carcinoma Cell Proliferation and Migration by Repressing Astrocyte Elevated Gene-1 (AEG-1) Expression

Influence of Phosphatidylinositide 3-Kinase Inhibitor LY294002 on the Expression of Hypoxia Inducible Factor-1Α and Growth of Human Glioma U251 Cells

Effect of LY294002 on the Proliferation and Invasion of Gastric Cancer Cell Lines

Combined Inhibition of AURKA and HSF1 Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma by Activating Endoplasmic Reticulum Stress

LY294002 induces p53-dependent apoptosis of SGC7901 gastric cancer cells

Abstract A12: Variation in Response to Triple VEGFR Inhibitor Tivozanib in Mouse Models of Hepatocellular Carcinoma